Clinical trial enrollments began today for Natick-based Boston Scientific Corp.’s third-generation drug-eluting coronary stent, the company said.
The company’s TAXUS Element stent system will undergo testing in approximately 1,500 patients at 100 national and international medical facilities.
The goal of the study, dubbed TAXUS PERSEUS, is to evaluate the efficacy and safety of the new stent compared to current Boston Scientific stents.
The new coronary stent features increased flexibility in arteries and a lower profile, along with increased strength compared to current stents, according to the company.
The principal investigators for the trial will be Dr. Dean J. Kereiakes, medical director at The Christ Hospital Heart and Vascular Center and The Lindner Research Center in Cincinnati, and Dr. Louis A. Cannon of the Cardiac and Vascular Research Center of Northern Michigan in Petoskey, Mich.
